EDIT Editas Medicine, Inc. - Common Stock
$2,90
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 5, 2026
Zakres 52 tyg.
$2–$5
43% of range
Ocena Analityków
BUY
18 analysts
Cena Docelowa
$6
+107% upside
P/E (TTM)
-1.6
ROE
-688.8%
Marża Zysku Netto
-395.0%
O Editas Medicine, Inc. - Common Stock Przegląd firmy z Wikipedii
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Czytaj więcej
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
EDIT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$2.90
Kapitalizacja Rynkowa
$284M
P/E (TTM)
-1.6
EPS (TTM)
$-1.80
Przychody (TTM)
$41M
Stopa dywidendy
—
ROE
-688.8%
D/E Dług/Kapitał
2.1
Zakres 52 tyg.
$2 – $5
EDIT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$41M
2016-12-31
→
2025-12-31
EPS
$-1.80
2019-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-166M
2016-12-31
→
2025-12-31
Marże
-395.0%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
EDIT
Mediana porównawcza
P/E (TTM)
-1.6
17.4
P/S (TTM)
7.0
52.3
P/B
10.4
4.8
EV / EBITDA
-1.2
—
Price / FCF (Cena / FCF)
-1.7
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
EDIT
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-394.9%
—
Net Profit Margin (Marża Zysku Netto)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
EDIT
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
2.1
—
Current Ratio (Wskaźnik bieżący)
3.5
7.7
Quick Ratio (Wskaźnik Szybkości)
3.5
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
EDIT
Mediana porównawcza
Revenue YoY (Przychody R/R)
25.4%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
27.2%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
-14.9%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
EDIT
Mediana porównawcza
EDIT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
18 analityków
- Mocne kupno 4 22,2%
- Kup 8 44,4%
- Trzymaj 4 22,2%
- Sprzedaj 2 11,1%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
8 analityków · 2026-08-16
Mediana
$5.00
Teraz
$2.90
Niski
$1.00
Wysoki
$15.00
Średni cel
$5.00
+72,4%
Średnia cel
$6.00
+106,9%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.03%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 marca 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 grudnia 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 września 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 czerwca 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 marca 2025 | $-0.92 | $-0.60 | -0.32% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 13
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Bilans 24
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Przepływy pieniężne 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Rentowność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Rachunek zysków i strat 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Bilans 24
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Przepływy pieniężne 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Wycena (TTM) 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $41M | $32M | $78M | $20M | $26M |
| Marża Operacyjna % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Zysk netto | $-160M | $-237M | $-153M | $-220M | $-193M |
| Rozwodniony EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 2.1 | 0.4 | — | — | — |
| Wskaźnik bieżący | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Wskaźnik Szybkości | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-166M | $-219M | $-137M | $-181M | $-172M |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 239 emitentów · $327.2M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 41 (+2 vs poprzedni kw.) | 22 (-4 vs poprzedni kw.) | 76 (+20 vs poprzedni kw.) | 42 (-9 vs poprzedni kw.) | +75.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36 000 000 | 11 111 111 | 11,00% | Akcje |
| RA CAPITAL MANAGEMENT, L.P. | $28 800 360 | 8 889 000 | 8,80% | Akcje |
| Commodore Capital LP | $28 800 360 | 8 889 000 | 8,80% | Akcje |
| ADAR1 Capital Management, LLC | $28 800 360 | 8 889 000 | 8,80% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $19 897 929 | 6 141 336 | 6,08% | Akcje |
| Paradigm Biocapital Advisors LP | $18 100 665 | 5 586 625 | 5,53% | Akcje |
| Opaleye Management Inc. | $12 512 653 | 3 861 930 | 3,82% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11 658 618 | 3 598 339 | 3,56% | Akcje |
| Woodline Partners LP | $11 519 810 | 3 555 497 | 3,52% | Akcje |
| Vivo Capital, LLC | $11 519 010 | 3 555 250 | 3,52% | Akcje |
| GordonMD Global Investments LP | $10 131 480 | 3 127 000 | 3,10% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $7 999 298 | 2 468 919 | 2,45% | Akcje |
| Logos Global Management LP | $7 199 280 | 2 222 000 | 2,20% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $7 134 030 | 2 201 290 | 2,18% | Akcje |
| STATE STREET CORP | $7 101 442 | 2 191 803 | 2,17% | Akcje |
| GOLDMAN SACHS GROUP INC | $6 763 843 | 2 087 606 | 2,07% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $4 318 842 | 1 332 976 | 1,32% | Akcje |
| Seven Fleet Capital Management LP | $4 310 820 | 1 330 500 | 1,32% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $4 201 156 | 1 296 653 | 1,28% | Akcje |
| MARSHALL WACE, LLP | $4 044 048 | 1 248 163 | 1,24% | Akcje |
| D. E. Shaw & Co., Inc. | $3 715 178 | 1 146 660 | 1,14% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 344 111 | 1 032 133 | 1,02% | Akcje |
| MACKENZIE FINANCIAL CORP | $2 844 856 | 878 042 | 0,87% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2 812 424 | 868 032 | 0,86% | Akcje |
| Nantahala Capital Management, LLC | $2 762 748 | 852 700 | 0,84% | Akcje |
| TWO SIGMA ADVISERS, LP | $2 509 405 | 1 224 100 | 0,77% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $2 407 158 | 742 950 | 0,74% | Akcje |
| BlackRock, Inc. | $1 813 920 | 559 852 | 0,55% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $1 616 750 | 498 997 | 0,49% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $1 545 801 | 477 099 | 0,47% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 521 180 | 469 500 | 0,46% | Opcja kupna |
| Eversept Partners, LP | $1 486 541 | 458 809 | 0,45% | Akcje |
| Casdin Capital, LLC | $1 441 800 | 445 000 | 0,44% | Akcje |
| PEAK6 LLC | $1 346 029 | 415 441 | 0,41% | Akcje |
| DIADEMA PARTNERS LP | $1 296 000 | 400 000 | 0,40% | Opcja kupna |
| BIT Capital GmbH | $1 056 240 | 326 000 | 0,32% | Akcje |
| Cubist Systematic Strategies, LLC | $994 094 | 286 482 | 0,30% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878 642 | 271 186 | 0,27% | Akcje |
| BANK OF AMERICA CORP /DE/ | $751 119 | 231 827 | 0,23% | Akcje |
| LPL Financial LLC | $748 813 | 231 115 | 0,23% | Akcje |
| Erste Asset Management GmbH | $736 000 | 230 000 | 0,22% | Akcje |
| IEQ CAPITAL, LLC | $705 623 | 217 785 | 0,22% | Akcje |
| Walleye Capital LLC | $595 703 | 183 859 | 0,18% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558 900 | 172 500 | 0,17% | Opcja sprzedaży |
| CITADEL ADVISORS LLC | $557 604 | 172 100 | 0,17% | Opcja sprzedaży |
| DAFNA Capital Management LLC | $552 323 | 170 470 | 0,17% | Akcje |
| Mariner, LLC | $548 500 | 169 291 | 0,17% | Akcje |
| Green Alpha Advisors, LLC | $505 589 | 156 046 | 0,15% | Akcje |
| PEAK6 LLC | $497 340 | 153 500 | 0,15% | Opcja kupna |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490 555 | 151 406 | 0,15% | Akcje |
| BARCLAYS PLC | $476 030 | 146 923 | 0,15% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $464 187 | 187 930 | 0,14% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445 030 | 137 355 | 0,14% | Akcje |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408 240 | 126 000 | 0,12% | Akcje |
| Point72 Asset Management, L.P. | $405 758 | 125 234 | 0,12% | Akcje |
| RHUMBLINE ADVISERS | $380 421 | 117 417 | 0,12% | Akcje |
| JPMORGAN CHASE & CO | $376 528 | 117 665 | 0,12% | Akcje |
| JANE STREET GROUP, LLC | $374 473 | 115 578 | 0,11% | Akcje |
| FMR LLC | $348 384 | 107 526 | 0,11% | Akcje |
| HSBC HOLDINGS PLC | $314 481 | 97 062 | 0,10% | Akcje |
| Bank of New York Mellon Corp | $309 378 | 95 487 | 0,09% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $303 462 | 93 661 | 0,09% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300 818 | 92 845 | 0,09% | Akcje |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300 226 | 92 094 | 0,09% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $300 011 | 92 596 | 0,09% | Akcje |
| CWM, LLC | $259 352 | 105 001 | 0,08% | Akcje |
| MORGAN STANLEY | $237 324 | 73 248 | 0,07% | Akcje |
| CITADEL ADVISORS LLC | $229 392 | 70 800 | 0,07% | Opcja kupna |
| OSAIC HOLDINGS, INC. | $222 928 | 68 806 | 0,07% | Akcje |
| SEI INVESTMENTS CO | $221 188 | 68 268 | 0,07% | Akcje |
| Nuveen, LLC | $221 188 | 68 268 | 0,07% | Akcje |
| Joel Isaacson & Co., LLC | $220 787 | 68 144 | 0,07% | Akcje |
| JANE STREET GROUP, LLC | $218 376 | 67 400 | 0,07% | Opcja sprzedaży |
| SIMPLEX TRADING, LLC | $207 275 | 63 974 | 0,06% | Akcje |
| MetLife Investment Management, LLC | $182 140 | 56 216 | 0,06% | Akcje |
| CITIGROUP INC | $182 052 | 56 189 | 0,06% | Akcje |
| CITADEL ADVISORS LLC | $173 923 | 53 680 | 0,05% | Akcje |
| MML INVESTORS SERVICES, LLC | $168 765 | 52 088 | 0,05% | Akcje |
| GROUP ONE TRADING LLC | $163 131 | 50 349 | 0,05% | Akcje |
| Creative Planning | $147 653 | 45 572 | 0,05% | Akcje |
| China Universal Asset Management Co., Ltd. | $143 934 | 44 424 | 0,04% | Akcje |
| WINTON GROUP Ltd | $141 588 | 43 700 | 0,04% | Akcje |
| Vanguard Global Advisers, LLC | $138 876 | 42 863 | 0,04% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $137 376 | 42 400 | 0,04% | Akcje |
| Graham Capital Management, L.P. | $134 369 | 41 472 | 0,04% | Akcje |
| Quinn Opportunity Partners LLC | $129 600 | 40 000 | 0,04% | Akcje |
| Invesco Ltd. | $128 178 | 39 561 | 0,04% | Akcje |
| Vanguard Personalized Indexing Management, LLC | $124 108 | 38 305 | 0,04% | Akcje |
| MERCER GLOBAL ADVISORS INC /ADV | $121 967 | 37 644 | 0,04% | Akcje |
| Balyasny Asset Management L.P. | $121 947 | 37 638 | 0,04% | Akcje |
| AXQ CAPITAL, LP | $118 104 | 36 452 | 0,04% | Akcje |
| Nuveen Asset Management, LLC | $113 934 | 89 712 | 0,03% | Akcje |
| SCS Capital Management LLC | $113 400 | 35 000 | 0,03% | Akcje |
| Police & Firemen's Retirement System of New Jersey | $109 749 | 33 873 | 0,03% | Akcje |
| Thrive Wealth Management, LLC | $108 540 | 33 500 | 0,03% | Akcje |
| TWO SIGMA SECURITIES, LLC | $107 367 | 33 138 | 0,03% | Akcje |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102 359 | 31 207 | 0,03% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $98 159 | 30 296 | 0,03% | Akcje |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89 683 | 27 680 | 0,03% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88 339 | 27 265 | 0,03% | Akcje |
Insiderzy spółki 32 insiderów · 13 dyrektorzy generalni · 15 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 czerwca 2026 S | 248 313 | 0 | 1 | $-41 543 |
| MULLEN JAMES C | CEO | 3 stycznia 2022 S | 75 898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 lutego 2021 S | 43 760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 stycznia 2019 S | 1 204 966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 stycznia 2022 S | 31 462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 lutego 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 lipca 2026 S | 62 369 | 0 | 2 | $-15 133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 grudnia 2021 A | 31 498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 grudnia 2021 A | 22 675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 grudnia 2021 A | 41 785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 października 2019 A | 25 000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 marca 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 lutego 2018 A | 4 000 | 0 | 0 | $0 |
| Elliott M. Levy | Dyrektor | 17 czerwca 2026 A | — | 0 | 0 | $0 |
| David Scadden | Dyrektor | 17 czerwca 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Dyrektor | 17 czerwca 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Dyrektor | 17 czerwca 2026 A | 22 700 | 0 | 0 | $0 |
| Andrew Hirsch | Dyrektor | 17 czerwca 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Dyrektor | 3 września 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Dyrektor | 3 czerwca 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Dyrektor | 15 czerwca 2018 A | 35 000 | 0 | 0 | $0 |
| Douglas G. Cole | Dyrektor | 17 sierpnia 2017 J | 3 171 | 0 | 0 | $0 |
| Kevin Bitterman | Dyrektor | 15 czerwca 2017 A | 2 797 144 | 0 | 0 | $0 |
| Alexis Borisy | Dyrektor | 15 czerwca 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Dyrektor | 15 czerwca 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | Posiadacz 10% | 6 września 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Posiadacz 10% | 8 lutego 2016 C | 2 649 572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6 sierpnia 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3 sierpnia 2026 S | 14 292 | 0 | 2 | $-3 002 |
| Akshay Vaishnaw | — | 3 czerwca 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 grudnia 2020 M | 24 907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 marca 2017 M | 117 788 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 1 akcja
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 zgłoszenia | 18 września 2017 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 28 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32 319 SH | 8 sierpnia 2026 | Dziennie |
| GNOM · Global X Funds | 0,34% | 54 725 NS | 31 maja 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341 978 SH | 8 sierpnia 2026 | Dziennie |
| IBB · iShares Trust | 0,03% | 1 035 067 SH | 8 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8 268 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96 927 SH | 8 sierpnia 2026 | Dziennie |
| BIB · ProShares Trust | 0,02% | 3 611 NS | 31 maja 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1 527 NS | 31 maja 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823 535 SH | 8 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118 938 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575 834 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 461 967 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,01% | 2 583 050 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,01% | 42 610 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4 633 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476 309 NS | 31 maja 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3 622 NS | 31 maja 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32 379 NS | 31 maja 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3 660 NS | 31 maja 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120 119 SH | 8 sierpnia 2026 | Dziennie |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 maja 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2 922 NS | 31 maja 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96 350 NS | 31 maja 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19 020 SH | 8 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1 100 306 SH | 8 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4 890 144 SH | 8 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9 046 SH | 8 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7 608 SH | 8 sierpnia 2026 | Dziennie |